Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin

Yoshikazu Furusawa, Shinji Yamada, Shunsuke Itai, Masato Sano, Takuro Nakamura, Miyuki Yanaka, Saori Handa, Takuya Mizuno, Ken Maeda, Masato Fukui, Hiroyuki Harada, Mika K. Kaneko, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Podoplanin (PDPN), a type I transmembrane glycoprotein, is expressed in several body tissues, including podocytes of renal glomerulus, type I alveolar cells of lung, and lymphatic endothelial cells. PDPN activates platelet aggregation by binding to C-type lectin-like receptor-2 (CLEC-2) presented on platelets. Monoclonal antibodies (mAbs) against human-, mouse-, rat-, rabbit-, dog-, bovine-, and cat-PDPN have already been established. However, anti-horse PDPN mAbs have not yet been developed. In this study, we immunized mice with synthetic horse PDPN peptides and developed anti-horse PDPN mAbs. One of the established mAbs, PMab-202 (IgG1, kappa), was specifically able to detect horse PDPN in Chinese hamster ovary/horse PDPN (CHO/horPDPN) cells in flow cytometry experiments. PMab-202 was also able to detect endogenous horse PDPN expressed in and a horse kidney cell line, FHK-Tcl3.1, in flow cytometry and Western blot analyses. PMab-202 is expected to prove useful in investigating the function of horse PDPN.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
Issue number5
Publication statusPublished - 2018 Nov


  • PDPN
  • PMab-202
  • horse podoplanin


Dive into the research topics of 'Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin'. Together they form a unique fingerprint.

Cite this